Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $78.00.

LNTH has been the subject of a number of research reports. Truist Financial boosted their price target on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, Mizuho increased their price objective on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $71.27 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. Lantheus has a 1-year low of $47.25 and a 1-year high of $111.29. The company has a market cap of $4.73 billion, a PE ratio of 29.95 and a beta of -0.08. The stock has a fifty day moving average price of $66.65 and a 200 day moving average price of $59.38.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. M&T Bank Corp bought a new stake in Lantheus during the 4th quarter worth approximately $370,950,000. Farallon Capital Management LLC boosted its holdings in shares of Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after buying an additional 1,950,252 shares during the period. Assenagon Asset Management S.A. bought a new stake in shares of Lantheus during the third quarter worth $65,654,000. Norges Bank acquired a new stake in shares of Lantheus during the fourth quarter worth $76,197,000. Finally, Polaris Capital Management LLC bought a new stake in Lantheus in the 3rd quarter valued at $32,687,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.